AGCO and Bosch BASF Smart Farming Announce Joint Development and Commercialization of Smart Spraying Capabilities
6.4.2023 15:30:00 EEST | Business Wire | Press release
AGCO Corporation announced today that together with Bosch BASF Smart Farming it will integrate and commercialize Smart Spraying technology on Fendt Rogator sprayers, and jointly develop additional, new features.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230406005041/en/
Fendt Rogator 665 using the Smart Spraying Solution targeted spraying in a green-on-brown trial application. (Photo: Business Wire)
In May 2021, AGCO and Bosch BASF Smart Farming started the first trials of Bosch BASF Smart Farming’s innovative Smart Spraying Solution, which will deliver optimal herbicide savings without compromising weed control and will enable targeted spraying during day and night-time conditions. In addition to targeted spraying, the system will deliver integrated digital tools to turn the application data into actionable insights and improve yields and efficiency for farmers. Herbicide savings are delivered through sophisticated sensoring, automated sensitivity thresholds, access to Bosch BASF Smart Farming’s pest identification technology, and the use of Fendt Rogator’s robust application platform. AGCO will offer the system in the Americas and Europe starting in 2024.
Farmers will also be able to benefit from customized agronomic recommendations and reliable documentation within the same solution. The system will offer an end-to-end user experience through AGCO on-board and off-board controls and Bosch BASF Smart Farming’s integrated digital platform from xarvio® Digital Farming Solutions, with insights into the data gathered during the application.
Supported crops currently include corn, soy, cotton, canola, sunflower, and sugarbeet, with capabilities for more crops such as small grains being added over time.
“The progress we have made with Bosch BASF Smart Farming in developing a sustainable solution that maintains productivity while improving profitability and delivering clean fields with maximum savings is an excellent example of AGCO’s farmer focus,” said Seth Crawford, Senior Vice President and General Manager, Precision Ag & Digital, AGCO. “We look forward to our further collaboration with Bosch BASF Smart Farming as we work together to bring this solution to farmers and custom applicators around the world.”
“What makes our system unique is the combination of superior precision, digital tools and the agronomic expertise. With a 24/7 application capability, we create exceptional green-on-green and green-on-brown performance. This type of precision agronomics offering is a breakthrough to support farmers with less impact and higher yields,” said Matt Leininger, Managing Director North America, Bosch BASF Smart Farming.
About AGCO
AGCO (NYSE:AGCO) is a global leader in the design, manufacture and distribution of agricultural machinery and precision ag technology. AGCO delivers customer value through its differentiated brand portfolio including core brands like Fendt®, GSI®, Massey Ferguson®, Precision Planting® and Valtra®. Powered by Fuse® smart farming solutions, AGCO’s full line of equipment and services help farmers sustainably feed our world. Founded in 1990 and headquartered in Duluth, Georgia, USA, AGCO had net sales of approximately $12.7 billion in 2022. For more information, visit www.AGCOcorp.com. For company news, information, and events, please follow us on Twitter: @AGCOCorp. For financial news on Twitter, please follow the hashtag #AGCOIR.
About Bosch BASF Smart Farming
Bosch BASF Smart Farming – a joint venture of Bosch and BASF – was established in 2021 to combine the best of two worlds: with the agronomic know-how from BASF and hardware expertise from Bosch, we create the farming of tomorrow, today. Combining precision technology, digital tools, and agronomic intelligence, we offer smart farming solutions that really work to make agriculture more productive, profitable, and sustainable. More information at: www.smartfarming.ag
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230406005041/en/
Contact information
Julie Ulbrich, AGCO | julie.ulbrich@AGCOCorp.com | +1 770-235-2943
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom